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Background: Activins are members of the TGF-ß superfamily of growth factors. First, we identified by expression
array screening that activin-B and follistatin are upregulated in human idiopathic pulmonary fibrosis (IPF). Next, we
wanted to clarify their specific role in lung fibrosis formation.
Methods: We used specific antibodies for activin-A and -B subunits and follistatin to measure and localize their
levels in idiopathic pulmonary fibrosis and control lung biopsies. To inhibit activin signaling, we used soluble activin
type IIB receptor fused to the Fc portion of human IgG1 (sActRIIB-Fc) in two different mouse models of pulmonary
fibrosis.
Results: Activin-B and follistatin mRNA levels were elevated in the human IPF lung. Immunoreactivity to activin-A, -B
and follistatin localized predominantly to the hyperplastic, activated alveolar epithelium, but was also seen in
inflammatory cells. Mice treated with sActRIIB-Fc showed increased skeletal muscle mass and a clear reduction
in alveolar cell counts in bronchoalveolar lavage fluid, but no significant antifibrotic effect in the lung was observed.
Conclusions: The upregulation of activin-B and follistatin in IPF is a novel finding. Our results indicate that activin
inhibition is not an efficient tool for antifibrotic therapy, but could be useful in reducing alveolar cellular response to
injury. Activin-B and follistatin levels may be useful as biomarkers of IPF.
Keywords: Activins, Follistatin, Idiopathic pulmonary fibrosis, Mouse fibrosis modelBackground
Idiopathic pulmonary fibrosis (IPF) is a disease with a
prognosis worse than many cancers [1]. Promising ad-
vances in the treatment of IPF have emerged recently
[2-4]. The pathobiological alterations in IPF have been
related to injury-induced epithelial cell activation and
enforced transforming growth factor (TGF)-ß signaling.
The clinical course of IPF is unpredictable; some pa-
tients develop acute worsening of the disease with no* Correspondence: marjukka.myllarniemi@helsinki.fi
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article, unless otherwise stated.identifiable cause, i.e. acute exacerbations, where the
mortality can be up to 70% [5]. The histopathological
finding in IPF exacerbation is diffuse alveolar damage
superimposed on the typical IPF histopathology of usual
interstitial pneumonia (UIP) [6].
Activins belong to the TGF-ß superfamily of growth
factors and are composed of two inhibin ß subunits.
They signal mainly through activin type I and II trans-
membrane serine/threonine kinase receptors (ActRI and
II) inducing Smad signaling pathways [7]. Both activin-A
and -B signal through either ActRII or ActRIIB, as type
II receptor and a common type I receptor known as
ActRIB, or activin-like kinase 4 (ALK-4) to activate the
Smad2/3 pathway. However, Smad signaling activation
by activin-A and -B is not identical in target cells asntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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or ALK-7 type I receptor for Smad2/3 activation [8].
Activin-B can also act as a bone morphogenetic protein
(BMP)-like factor by inducing Smad1/5/8 phosphorylation
via type I BMP receptor BMPRIA or ALK-3 [9]. It is there-
fore important to distinguish between the relative roles of
these two activins and their inhibitors in different tissue
and disease entity contexts.
Activins were initially identified for their role in regu-
lating reproductive processes. Later they were found to
be involved in the regulation of inflammatory and tissue
repair processes [10]. In the lung, increased activin levels
are observed in antigen-induced airway inflammation [11],
they are also associated with acute injury [12]. Activin-A
immunoreactivity has been shown to increase in IPF and
acute lung injury autopsy specimens [13]; activins have
also been shown to associate with lung fibroblast prolifera-
tion and differentiation [14]. Adenoviral expression of
activin-A in mouse lung epithelium leads to respiratory
pathology similar to human acute respiratory distress syn-
drome involving inflammation, fibrosis, and tissue remod-
eling [12]. Follistatin is a natural activin-blocking molecule
that is highly expressed in the ovary but is also found
in a number of extragonadal tissues; its role is likely
that of a natural quenching molecule that limits acti-
vin effects at the tissue level. Follistatin has been shown
to suppress bleomycin-induced lung fibrosis and carbon
tetrachloride-induced liver fibrosis in experimental mouse
models [15,16]. The contribution of the activin/follistatin
system in the development or progression of IPF is
not well known. Functional studies on lung fibrosis
or localization of activin-B in the lung have not been
published.
This study was designed to screen for potential novel
indicators of TGF-ß signaling in the human IPF lung.
We found that activin-B and follistatin mRNA were up-
regulated in the IPF lung. We also identified an increase
in the immunoreactivity of activin-A, -B and follistatin
in the pathological, hyperplastic epithelium in the hu-
man IPF lung. Activin neutralization by using a soluble
ActRIIB receptor fused to the Fc portion of human IgG1
[12,17] reduced bronchoalveolar lavage fluid (BALF)
cellular responses to injury in two different mouse models
but failed to show any significant antifibrotic effects.
Methods
Human tissue samples
An approval for collecting tissue for research purposes
from diagnostic clinical samples was received from the
Helsinki University Hospital Ethics Board (HUS 426/13/
03/01/09). All patients that participated to the study
gave written informed consent except for the lung trans-
plant donors that were deceased. A permission to use
tissue samples from deceased patients was obtained fromthe national supervisory authority of welfare and health
(3317/05.01.00.06/2011).
For RNA isolation and expression array analysis, four
IPF and four control specimens were carefully chosen in
order to minimize variability due to confounding factors.
Each patient’s medical history, HRCT evaluation and
clinical course of the disease indicated that they had
classical IPF; this was confirmed with lung biopsy. Three
IPF biopsies were collected from explanted lungs at the
time of transplantation, one from a diagnostic biopsy
procedure. The mean age of the IPF patients was 55
(range 49–57), and all patients were nonsmokers. Con-
trol specimens in the array analysis consisted of patients
who underwent surgical lobectomy due to benign pul-
monary tumor (hamartoma), showed normal pulmonary
histology, and had normal lung function (all patients
were nonsmokers, mean age 64, range 59–70).
For immunohistochemical analyses, samples from diag-
nostic biopsies or lung transplantation, or both, were
obtained from the University of Helsinki, Department of
Pathology. Clinical records and HRCT scans were evalu-
ated from all the patients according to the current guide-
lines to ensure correct diagnosis. Control lung samples
were biopsies or segments of healthy donor lung that was
used for transplantation. All the IPF patients had typical,
advanced UIP pattern in the biopsy of the explanted lung.
All the IPF patients were male. Their mean forced vital
capacity (FVC % from predicted) before the operation was
47, and the mean volume-adjusted diffusing capacity was
60.5. Mean patient age was 52 (range 40–59).
Antibodies
Mouse monoclonal antibodies (mAbs) against human
activin-A, activin-B and follistatin subunits (encoded by
INHBA, INHBB and follistatin genes, respectively) were
generated by AnshLabs LLC (Webster, TX) by using
peptide-conjugates that contain peptide sequences of the
C terminal portion of the mature region of each activin.
The activin-reacting mAbs were initially selected against
commercially available human recombinant activin-A
and -B (R&D Systems, Minneapolis, MN) and internally
produced chinese hamster ovary (CHO) cell derived
human recombinant activins at AnshLabs (not shown).
The mAb 18/26A (for activin-A/INHBA), mAb 12/9A
(for activin-B/INHBB) and mAb 4/73C for follistatin were
selected for immunohistochemistry based on their specifi-
city in Western blots and specific reactivity towards
granulosa cells in human ovarian sections (not shown).
Immunohistochemistry
Paraffin-embedded tissue sections were deparaffinized in
xylene and rehydrated in graded alcohol. Antigens were
retrieved by heating the sections in 0.01 M citrate buffer
(pH 6.0). For immunostaining, Novolink Polymer Detection
Myllärniemi et al. BMC Pulmonary Medicine 2014, 14:170 Page 3 of 14
http://www.biomedcentral.com/1471-2466/14/170System (Novocastra, Leica Biosystems Newcastle Ltd.,
Newcastle Upon Tyne, UK) was used according to the
manufacturer’s protocol. The sections were exposed to
the primary antibodies at room temperature for 1 h.
The bound antibodies were visualized by DAB. The sec-
tions were counterstained with Mayer’s haematoxylin and
mounted on glass slides.
SDS-PAGE and immunoblotting
Snap-frozen and subsequently pulverized mouse lung was
lysed on ice for 15 min in RIPA buffer (50 mM Tris-HCl,
pH 7.4; 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.2% so-
dium deoxycholate) that contained protease inhibitors
(Pierce, Rockford, IL). Protein concentrations were mea-
sured using a BCA protein assay kit (Pierce, Rockford, IL).
Equal amounts of protein were separated by SDS-PAGE
using 4-20% gradient Tris-glycine gels (Lonza, Basel,
Switzerland) and transferred to nitrocellulose membranes
(Bio-Rad, Hercules, CA) using a semi-dry blotting system
(Bio-Rad). Membranes were blocked with 5% non-fat
milk in TBS/0.05% Tween-20 to prevent non-specific
binding of the antibodies. Next, they were incubated with
anti-inhibin ßB monoclonal antibody (46A/F) [18], and then
with biotin-conjugated anti-mouse secondary antibody
(DAKO, Glostrup, Denmark) in TBS/0.05% Tween-20 con-
taining 5% bovine serum albumin at room temperature.
After several washing steps, the final detection was per-
formed using horseradish peroxidase-conjugated streptavi-
din and an enhanced chemiluminescence Western blotting
detection system (Amersham, Freiburg, Germany). Ana-
lyses of protein band intensities were performed using the
Scion Image analysis program (Scion Corporation).
RNA isolation and quantitative RT-PCR
Total RNA was extracted from homogenized lung tissue
samples with an RNeasy Mini Kit (Qiagen GmbH,
Hilden, Germany) and reverse transcribed using iScript
cDNA synthesis kit (Bio-Rad). The cDNAs were amplified
using TaqMan Assays-on-Demand gene expression prod-
ucts (Applied Biosystems) and CFX96 Real-time PCR de-
tection system (Bio-Rad). Control amplifications directly
from RNA were performed in order to rule out DNA con-
tamination. The relative gene expression differences were
calculated with the comparative delta delta cycle threshold
(ΔΔCT) method, and the results have been reported as
mRNA expression levels normalized to the levels of a gene
with a constant expression (TATA-binding protein).
Expression PCR array
Pathway-specific PCR array (#PAHS-035; SABiosciences)
was used to analyze mRNA expression levels of genes
associated with the TGF-ß/BMP signaling pathway. Fol-
lowing the manufacturer’s instructions, reverse tran-
scription was performed using DNase I treated RNA andRT2 First Strand Kit (SABiosciences) followed by PCR
amplification using CFX384 real-time PCR detection sys-
tem (Bio-Rad). Gene expression levels in control lung tis-
sue (n = 4) were compared to the levels in IPF lung tissue
(n = 4) using SABioscience PCR data analysis tools.
sActRIIB-Fc production
The recombinant fusion protein containing the ectodo-
main of human ActRIIB fused to the Fc domain of human
IgG1 (sActRIIB-Fc) was produced in-house as described
previously [12,17]. For the final production of the chimeric
protein, CHO cells were transfected with the expression
construct via lipofection (Fugene 6; Roche) and selected
with puromycin (Sigma-Aldrich). During selection, cells
were grown in DMEM supplemented with 2 mM L-glu-
tamine, 100 μl/ml streptomycin, 100 IU/ml penicillin, and
10% fetal calf serum. For large-scale expression, cells were
adapted to CD OptiCHO medium (Gibco) supplemented
with 2 mM L-glutamine and grown in suspension in an
orbital shaker. Cell culture supernatants were clarified by
filtration through 0.22 μm membrane (Steritop, Millipore).
1 M NaCl, 5 mM imidazole, and Protease Inhibitor
Cocktail (Thermo Scientific) were added into the clarified
supernatants, and the solution was pumped through a
HisTrap FF Crude column (GE Healthcare Life Sciences,
Uppsala, Sweden) at 4°C. Protein was eluted with increas-
ing imidazole concentrations, dialyzed against phosphate-
buffered saline (PBS), and finally concentrated with
Amicon Ultra concentrator (30 000 MWCO, Millipore).
Mouse models of IPF
A permission to use experimental animals was received
from the regional state administrative agency of South-
ern Finland (ESAVI/871/04.10.03/2012) and their ethical
board. The reporting on animal experiments was done
in accordance to the Animal Research: Reporting of In
Vivo Experiments (ARRIVE) guidelines (http://www.nc3rs.
org.uk/page.asp?id=1357). Male C57b6J mice were used
for the experiments. The mice were exposed to either cro-
cidolite asbestos fibers (0.5 mg/50 μl sterile PBS) or silicon
dioxide (SiO2) (Sigma; 2.5 mg/50 μl sterile PBS) as de-
scribed previously [19]. Two subsequent oropharyngeal
aspiration doses were given on days 0 and 7 of the experi-
ment to ensure even exposure of all animals. The mice
were harvested on day 28 after exposure. sActRIIB-Fc was
administered via i.p. injections at a dose of 5 mg/kg twice
a week during the entire observation period. Knowing that
sActRIIB-Fc increases body mass, the mice were weighed
at each drug injection to monitor the drug effect
[17,20,21]. At the time of harvest, mice were euthanized
with carbon dioxide, after which BALF samples were col-
lected by injecting 2×300 μl of sterile PBS to the trachea.
The BALF cells were counted using Bio-Rad TC10 auto-
mated cell counter. Differential cell counts were obtained
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centrifuge preparates: 150 μl BALF was loaded to cytospin
chambers containing Superfrost Ultra Plus glass slides
(Menzel GmbH & Co KG, Braunschweig, Germany) and
centrifuged for 8 minutes, 500 rpm. The right lung was
snap-frozen and subsequently pulverized for hydroxypro-
line and RNA and/or protein analysis. The left lung was
fixed with 3% paraformaldehyde for histological analysis.
For sActRIIB-Fc administration and analysis of possible al-
terations in body composition due to asbestos or silica ex-
posure or both, hindlimb skeletal muscles and epididymal/
retroperitoneal fat was prepared and weighed using an
analytical scale. Histological evaluation was performed as
described and validated previously [22].
Statistical analyses
All comparisons were made using nonparametric tests
with SPSS software (IBM). Multiple group comparisons
were made using Kruskal-Wallis test, and two-group com-
parisons were made using Mann-Whitney test. If mul-
tiple comparisons were made between two groups, the
Bonferroni correction was applied to P values. P values
below 0.05 were considered statistically significant.
Results
Expression of activin-A, -B and follistatin in human IPF
lung
Total RNA was isolated from frozen human lung tissue
samples from control subjects and IPF patients. A com-
mercial PCR array was used to analyze the mRNA ex-
pression levels of the TGF-ß/BMP pathway genes (see
Methods). As expected, the major fibrotic collagen genes
COL1A1 (p = 0.011), COL1A2 (p = 0.005) and COL3A1
(p = 0.018) were significantly upregulated in the IPF pa-
tient lungs (Figure 1A). In addition, LTBP-1 (p = 0.002),
IGF-1 (p = 0.011) and IGFBP3 (p = 0.002) were found up-
regulated as previously described [23-25]. A trend for in-
creased levels of INHBB mRNA (p = 0.088), which
encodes activin-B subunit was observed. The mRNA ex-
pression of the activin inhibitor protein follistatin was also
notably increased in the IPF lungs (p = 0.005). Upregula-
tion of INHBB and FST mRNA levels were confirmed by
quantitative RT-PCR (Figure 1B). The TGF-ß/BMP path-
way genes BMP2 (p = 0.072), BMP3 (p = 0.005), NOG (p =
0.04), FOS (p = 0.087) and JUN (p = 0.083) were downreg-
ulated in the IPF lungs.
Immunoreactivity for activin subunits was markedly
increased in human IPF/UIP tissue when compared to
controls, especially in the IPF/UIP lungs’ hyperplastic al-
veolar epithelial cells (Figure 2 and Table 1). Follistatin
immunoreactivity was seen in the control and IPF lungs
at high intensity. In the IPF/UIP tissue, high-intensity
follistatin staining was seen in the activated alveolar
epithelium and parenchymal macrophages. In controllungs, immunoreactivity was seen in macrophages or
type-II-appearing cells or both. In control samples, immu-
noreactivity was observed in some alveolar macrophages
and the bronchial epithelium for inhibin ßA and follistatin,
and for the inhibin ßB subunit mainly in the bronchial
epithelium. In IPF/UIP tissue, immunoreactivity for in-
hibin ßA subunit was observed in the activated alveolar
epithelial cells, macrophage-appearing cells in the lung
parenchyma, and alveolar space, whereas fibroblastic foci
in the lung parenchymal tissue were negative (Figure 2).
Inhibin ßB antibody showed immunoreactivity specifically
in hyperplastic alveolar epithelial cells and bronchial
epithelial cells. Macrophages remained mostly negative
for inhibin ßB in the IPF/UIP lung.
Expression of activin-A and -B in mouse models of
pulmonary fibrosis
Next, we analyzed the expression of activin subunits in
two different mouse models of IPF, asbestos-induced
fibrosis and silicon dioxide (silica)-induced fibrosis. In
both models progressive fibrosis is observed, and the
histopathological alterations resemble human IPF/UIP:
patchy areas of fibrosis and inflammatory cell aggregates
and areas of preserved normal lung architecture. In
control mice, Inhbb mRNA was expressed at 7–10 fold
higher levels than Inhba mRNA (Figure 3A). In both
models, Inhba mRNA was markedly increased in the
fibrotic lung tissue, whereas Follistatin levels remained
essentially unaltered (Figure 3A). Interestingly, in the
silica-induced fibrosis model also Inhbb mRNA levels
were significantly elevated in the lung tissue (Figure 3A).
The upregulation of activin-B in the silica-induced
fibrosis model was confirmed at the protein level
(Figure 3B and C).
Neutralization of activins in mice by using sActRIIB-Fc
As marked upregulation of activin subunits was observed
both in human and mouse IPF tissue, we explored the
effects of inhibition of activin function on inflammation,
fibrosis, and body composition using a soluble inhibitor
comprised of the extracellular portion of the ActRIIB fused
to the Fc portion of human IgG. Treatment with sActRIIB-
Fc started immediately after exposure of mice either to
asbestos or silica (day 1). After exposure, there was a tran-
sient reduction or slowing down in the weight gain of the
animals (Figure 4A). After two weeks, the mice treated
with sActRIIB-Fc showed a clear increase in body weight
when compared to both non-treated and non-treated,
non-exposed controls. By the end of the follow-up time,
the sActRIIB-Fc treated mice were approximately 4 g heav-
ier than the non-treated, exposed control animals in both
models. Since sActRIIB-Fc is known to block myostatin
and activin-A function as an inhibitor of muscle growth
[17,20,21] weight gain was expected. Measurements of
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Figure 1 INHBB and follistatin mRNA expression is increased in IPF lung. A. The mRNA expression levels of TGF-ß/BMP pathway genes in
human idiopathic pulmonary fibrosis (IPF) lung (N = 4) and control lung (N = 4) were measured using a PCR array. In the scatter plot, IPF group
is plotted against the control group. At least threefold differences in mRNA expression levels are indicated with green (upregulation) and red
(downregulation) color. INHBB and follistatin mRNA expression was increased 3.8-fold and 3.6-fold, respectively. Col, collagen; LTBP1, latent TGF-ß
binding protein; IGF, insulin-like growth factor; IGFBP, IGF binding protein; BMP, bone morphogenetic protein. B. INHBB and FST mRNA expression
levels were confirmed by quantitative RT-PCR.
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(Figure 4B) as well as extensor digitorum longus, soleus
and tibialis anterior muscle mass (not shown) showed sig-
nificant increase in sActRIIB-Fc-treated animals, while no
alterations were observed in non-treated, exposed animals(Figure 4B). On average, muscle masses were increased by
35.9% (asbestos-exposed) and 30.7% (silica-exposed) in
the sActRIIB-Fc-treated animals. Heart mass was compar-
able in all the animal groups (not shown). These results
confirm the expected function of the soluble inhibitor in
IPF/
UIP
Ctrl
Activin A, Inhibin Activin B, Inhibin A B
FF
FF
Follistatin
Figure 2 Activin-A, -B and follistatin immunoreactivity in human usual interstitial pneumonia (UIP) lung tissue and control lung samples.
Activin-A immunoreactivity (upper panel, left) is observed in hyperplastic alveolar epithelial cells (arrowheads) overlying fibroblastic foci (FF).
Occasionally, macrophage-appearing cells in the lung parenchyma stain positive. Activin-B immunoreactivity is similarly observed in areas
of hyperplastic epithelial cells and, to a lesser extent, in parenchymal inflammatory cell infiltrates. Follistatin expression is observed at a
high intensity in activated alveolar epithelial cells. Staining is also seen in lung bronchial epithelial cells (activins) and alveolar cells (follistatin), shown
in the control (Ctrl) lung sections, lower panel.
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to significant amounts of silica or asbestos do not lead to
permanent muscle atrophy.
Epididymal fat mass was measured in all the animal
groups and retroperitoneal fat mass in the silica model. In
mice exposed to asbestos, epididymal fat mass decreased
(Figure 4C) in both the treated and non-treated groups. InTable 1 Localization of inhibin subunit antibody immunoreac
fibrosis (IPF) lung
Patient Inhibin ßA Inhibin
Localization (H)AEC BE MΦ (H)AEC
Ctrl1 - - ++ -
Ctrl2 - + + -
Ctrl3 - + + -
Ctrl4 - - - -
Ctrl5 - - - -
IPF/UIP1 ++ ++ ++ +
IPF/UIP2 +++ ++ +++ +
IPF/UIP3 - - - -
IPF/UIP4 +++ +++ +++ +
IPF/UIP5 ++ ++ ++ +
The histopathological finding of IPF is usual interstitial pneumonia (UIP). (H)AEC, (hypesilica-exposed mice, epididymal fat mass decreased margin-
ally with a further decrease in the sActRIIB-Fc-treated mice
(Figure 4C). Furthermore, retroperitoneal fat mass de-
creased in both silica-exposed animal groups (not shown).
These results suggest that fibrotic mice have a reduced fat
mass, which may reflect increased energy consumption due
to either inflammation or increased respiratory work.tivity in human control (Ctrl) and idiopathic pulmonary
ßB Follistatin
BE MΦ (H)AEC BE MΦ
- - - +++ ++
+ + - - ++
+ + - +++ +++
+ + - ++ ++
- - - ++ ++
+ - +++ +++ +++
+ - ++ ++ ++
+ - +++ +++ +++
- - ++ ++ +++
++ - +++ +++ +++
rplastic) alveolar epithelial cells; BE, bronchial epithelial cells; MΦ, macrophages.
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Figure 3 Levels of Activin mRNA and protein in the mouse lung. A. Inhba and Inhbb expression levels in asbestos (Asb)- and silica-exposed
mice at 30 days after oropharyngeal aspiration. The expression levels are shown relative to the expression levels of Inhba in control-1. Control
(Ctrl) animals are non-treated and non-exposed mice. B. Immunoblotting analyses of lung tissue lysates using anti-inhibin ßB specific antibodies.
The mobility of recombinant 25 kDa human activin-B (C, control) is shown on the right. Ponceau staining indicates equal loading. C. Quantification of
inhibin ßB band intensities.
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composition and tissue inflammation in fibrotic mice
BALF total cell counts increased in mice exposed to as-
bestos or silica as expected (Figure 5A). In both models,
there was a clear decrease of alveolar total cell numbers
in the animals treated with the inhibitor, suggesting that
neutralization of activins has an attenuating effect on
the cellular response to alveolar injury. The relative
numbers (percentages) of neutrophils and lymphocytes
increased significantly in asbestos-exposed mice, and
this was not altered by treatment with sActRIIB-Fc
(not shown). There were no significant changes in
tissue inflammatory cell numbers (Figure 5B).
Effect of activin neutralization on lung profibrotic gene
expression and fibrosis in two different mouse fibrosis
models
As the upregulation of activins was observed in human
lung tissue in relationship to lung fibrosis, we wanted to
test whether efficient blockade of activins could modu-
late the fibrotic response in these two different mouse
models of progressive lung fibrosis. Lung tissue mRNAexpression levels of Inhba were not altered by treatment
with sActRIIB-Fc (not shown). There was a slight, but
statistically nonsignificant, decrease in Inhbb expression in
sActRIIB-Fc-treated asbestos-exposed mice (Figure 6A). In
agreement with the known regulatory effect of activin on
follistatin expression [26], treatment with the sActRIIB-Fc
decreased Follistatin mRNA expression in the lung tissue
of these mice (Figure 6A). Interestingly, there was also
a trend towards decreased mRNA expression of major
fibrotic genes (Col1A1, Col3A1, and tenascin-C) in sActRIIB-
Fc treated asbestos-exposed animals (Figure 6B). How-
ever, these alterations were not reflected in tissue
hydroxyproline levels (Figure 6C), but there was a 20%
decrease in the histological fibrosis score evaluated from
haematoxylin-eosin-stained lung tissue sections in the
asbestos-exposed sActRIIB-Fc treated animals in compari-
son to controls (Figure 7). In contrast to what was ob-
served in the asbestos-exposed animals, there was no
reduction of lung tissue Follistatin mRNA expression in
silica-exposed, sActRIIB-Fc-treated mice (Figure 6A).
Expression of fibrotic genes and histological fibrosis score
tended to further increase slightly in the treated animals
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Figure 4 Effect of activin inhibition to mouse body composition after particulate exposure. A. Effect of activin inhibition using sActRIIB-Fc
on body mass of mice exposed oropharyngeally to either asbestos or silica dust. E1 and E2 show time points of dust exposure. B. Effect of activin
inhibition on skeletal muscle mass. In asbestos-exposed animals, 5 animals with equal starting mass were chosen for measurement. In silica-exposed
animals N = 9 and in controls N = 6. C. Epididymal and retroperitoneal fat masses of mice treated with sActRIIB-Fc and exposed to either asbestos
(Asb, A; N = 5/group) or silica (B; N = 9 in the exposed animal groups and N = 5 in the control (Ctrl) group).
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Figure 5 Effect of activin inhibition to lung inflammation in experimental fibrosis. A. Effect of activin inhibition using sActRIIB-Fc on
bronchoalveolar lavage fluid total cell numbers in asbestos (Asb)- and silica-exposed mice. B. Effect of sActRIIB-Fc on inflammatory cell
score from paraffin sections of these mice (tissue inflammation). P values from Kruskal-Wallis (comparing three groups) and MannWhitney
U test (comparing two groups).
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fibrosis formation in these two mouse models is dif-
ferent. Hydroxyproline levels were unaltered by sActRIIB-Fc
(Figure 6C).
Discussion
TGF-ß family members are key regulators in a number of
fibrotic tissue processes. TGF-ß1 is the major pro-fibrotic
isoform associated with the pathogenesis of IPF, and high
levels of the signal transducer protein P-Smad2/3 are found
in the hyperplastic epithelium and throughout the lungparenchyma [23]. BMPs counterbalance TGF-ß-mediated
processes and induce signaling mainly through P-Smad1/
5/8. Downregulation of BMP-6 is associated with increased
renal fibrogenesis in mice [27], the BMP inhibitor protein
gremlin is highly upregulated in the IPF lung [28], and the
therapeutic administration of BMP-7 in a number of dif-
ferent experimental models reverses fibrotic alterations
[29-31]. Increased activin-A levels are associated with
acute respiratory injury [12]. However, the role of activin
isoforms in lung fibrosis is less well characterized. Activins
signal mainly through the P-Smad2/3 pathway, but recent
Figure 6 Effect of activin inhibition by sActRIIB-Fc in asbestos (Asb)- and silica-exposed mice (A). Fibrosis-related genes collagen (Col1A1,
Col3A1), smooth muscle actin (Sma), fibronectin (Fn), and tenascin-C (Tnc) relative mRNA levels are shown in B. Lung total hydroxyproline (HYP) levels
(C) did not show any significant alterations between groups treated with sActRIIB-Fc and the non-treated control. P values from Kruskal-Wallis
(comparing three groups) and Mann-Whitney U test (comparing two groups) are indicated in the figure.
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by activin-B [9]. In this study, activin-B was highly expressed
in the human and mouse fibrotic lung, and follistatin was
upregulated in the human IPF lung. Previously, upregula-
tion of activin-A has been reported in human autopsy
specimens [13] and in mice after bleomycin challenge [15].To study possible antifibrotic effects in vivo, we used
two different models of progressive fibrosis where activin
subunits were expressed differently (in the asbestos model
only activin-A was upregulated, whereas in the silica
model both activin-A and -B were upregulated). In
asbestos-exposed mice Inhba mRNA levels were elevated,
Figure 7 Effect of activin inhibition to fibrotic alterations in experimental fibrosis. The histological fibrotic alterations related to asbestos
(Asb) and silica exposure, and the effect of sActRIIB-Fc to these alterations in mice (A). The photomicrographs (B) show representative
haematoxylin-eosin-stained sections from the treated and non-treated groups in both the asbestos- and silica-exposed groups. P values
from Kruskal-Wallis (comparing three groups) and Mann-Whitney U test (comparing two groups) are indicated in A.
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sActRIIB-Fc reduced BALF cell counts; a trend towards
reduced expression of fibrotic genes such as Col1A1,
Col3A1 and tenascin-C was also observed. Furthermore,
tissue fibrosis score measured from haematoxylin-eosin-
stained tissue sections indicated a 20% decrease in fibrotic
alterations. sActRIIB-Fc reduced Follistatin mRNA ex-
pression in asbestos-exposed animals, indicating possible
functional neutralization of activin-A in lung tissue. The
hydroxyproline level, which is usually used to measurethe effects of antifibrotic medication in experimental
models, was not reduced. In silica-exposed mice, we
were unable to show any effects on fibrosis, except for
a slight increase in histopathological alterations. Taken
together, these results indicate that the neutralization of
activins is not sufficient to extensively reduce fibrosis,
despite small histological alterations in the treated mice.
We did find a useful correlation of collagen and tenascin
mRNA levels with the observed histopathologial alter-
ations: there was a trend towards increased expression
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score in the sActRIIB-Fc-treated silica-exposed mice and,
vice versa, with increased fibrotic changes these genes
were upregulated. These results indicate that more
sensitive assays than hydroxyproline measurements could
be useful in the quantification of fibrosis in mouse models.
Localization of activin subunits was possible in human
but not in mouse tissue due to lack of suitable antibodies.
Specific immunoreactivity for activin-A and -B was
observed in the hyperplastic alveolar epithelium, a hall-
mark pathological finding of human IPF/UIP histo-
pathology. Loss of epithelial cell integrity has been
recognized as a key process in pulmonary fibrosis [32].
There is a need for specific disease markers, and activin-B
can be considered to be a potential marker of alveolar
epithelial cell activation. The neutralization of activins by
sActRIIB-Fc was not sufficient to convincingly reduce
fibrosis in two separate mouse models of pulmonary
fibrosis. However, the inhibition of activin activity was
found to contribute to the alveolar cellular response to
particulate exposure without directly affecting inflamma-
tory cell numbers (alveolar and tissue infiltrating neutro-
phils and lymphocytes). This result supports the previous
finding that sActRIIB-Fc treatment may be beneficial in
the reduction of acute alveolar injury [12]. In itself, an
injury-decreasing compound would be welcome in clinical
use as a potential therapeutic molecule for acute IPF
exacerbation, an often-fatal condition that affects up to
15% of IPF patients [33]. So far, no clinical trials have had
consistent effects on IPF exacerbation [2-4]. If further
developed for clinical use, activin inhibition could be
considered as a candidate rescue therapy for acute IPF
exacerbation.
Our results indicate that the use of multiple experimen-
tal models in therapeutic studies is crucial. The induction
of the expression of activin subunits was different in the
two models used for activin neutralization experiments,
which is likely to affect the outcome. Strong induction of
activin-B, similar to human IPF patient samples, associ-
ated with silica-induced fibrosis. Activin-B localization in
human activated epithelium suggests pathologic function;
however, the recent identification of the ALK-3/P-Smad1/
5/8 pathway as an alternative mediator of activin-B signals
[9] indicates a more complicated signaling system. The
use of sActRIIB-Fc, which can sequester in addition to
activins also myostatin, nodal, and certain BMP isoforms,
notably BMP-4 and BMP-7, may also inhibit positive
repair signals [34]. Furthermore, muscle growth induced
by inhibition of myostatin function in sActRIIB-Fc-treated
animals may contribute to a profibrotic microenviron-
ment. Follistatin treatment has been found to inhibit
bleomycin-induced lung inflammation and subsequent
fibrosis [16], indicating that blocking activin function can
be beneficial.Conclusions
We report here an original observation that activin-B and
follistatin are upregulated in the human IPF lung, and that
activin-A, -B and follistatin protein localize to the acti-
vated, pathologic alveolar epithelium in the human IPF/
UIP lung. A high level of upregulation and disease-specific
localization of activin-B in the IPF lung may indicate that
activin-B could have potential as a biochemical marker for
IPF progression. Epithelial cell activation in IPF is cur-
rently considered as a hallmark of the pathogenesis of IPF.
Endoplasmic reticulum (ER) stress, the reinduction of
developmental genes such as the BMP and Wnt pathway
genes are key elements that distinguish the IPF lung from
the healthy adult lung. In this study, we show marked
upregulation of yet another set of developmental genes,
activin-A, -B and follistatin, which are almost completely
absent from the healthy lung. Our findings by using
specific blocking indicate that activins are not directly
linked to disease progression or fibrosis generation but
show a clear reduction in the alveolar response to injury
in two mouse models of particulate exposure. Finally we
postulate, that activin-B as a soluble protein can have
potential as an IPF biomarker.
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